Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in advanced heart failure patients on heart transplant waiting list
NCT04782245Phase 2Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Hospices Civils de Lyon. Planned start Sep 2022; status: withdrawn.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04782245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782245.